Metabolic intolerance to exercise;Intolerancias metabólicas al ejercicio

Neurologia

Volumn 18, Issue 6, 2003, Pages 291-302

  Arenas, Joaquín ^a   Martin, M A ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Carnitine palmitoyltransferase; Exercise intolerance; Mitochondrial respiratory chain; Myoadenylate deaminase; Myoglobinuria; Myophosphorylase

Indexed keywords

AMMONIA; CARNITINE PALMITOYLTRANSFERASE; CYTOCHROME C OXIDASE; FIBRIC ACID DERIVATIVE; GLYCOGEN PHOSPHORYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOCHONDRIAL DNA; TRANSFER RNA;

COLD; CONFERENCE PAPER; DIET RESTRICTION; ENZYME DEFICIENCY; EXERCISE; EXERCISE TOLERANCE; FEVER; GENE MUTATION; GLYCOGEN STORAGE DISEASE TYPE 5; HUMAN; METABOLISM; MITOCHONDRIAL RESPIRATION; MYOGLOBINURIA; MYOPATHY; RESPIRATORY CHAIN;

ADENOSINE DEAMINASE; ANIMALS; CARNITINE O-PALMITOYLTRANSFERASE; EXERCISE; EXERCISE TOLERANCE; GLYCOGEN STORAGE DISEASE TYPE V; HUMANS; MITOCHONDRIA, HEART;

EID: 0042065408     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (88)

1. a ed. New York: McGraw-Hill, 1995;1554-76.
2. Gross M. Clinical heterogeneity and molecular mechanisms in inborn muscle AMP deaminase deficiency. J Inher Metab Dis 1997;20:186-92.
3. Felig P, Wahren J. Fuel homeostais in exercise. N Engl J Med 1975;293:1078-84.
4. a ed. New York: McGraw-Hill, 1995;1587-609.
5. Havel RJ. Caloric homeostasis and disorder of fuel transport. N Engl J Med 1972;287:1186-92.
6. Layzer RB. Muscle metabolism during fatigue and work. Baillieres Clin Endocrinol Metab 1990;4:441-59.
7. Arenas J, Ricoy JR, Encinas ER, Pola P, D'Iddio S, Zeviani M, et al. Carnitine in muscle, serum and urine of non-professional athletes: Effects of physical exercise, training, and L-carnitine administration. Muse Nerv 1991;14:598-601.
8. Layzer RB. How muscles use fuel. N Engl J Med 1991;324:411-2.
9. McArdle B. Myopathy due to a defect in muscle glycogen breakdown. Clin Sci 1951;10:13-35.
10. Schmidt R, Hammaker L. Hereditary absence of muscle phosphorylase (McArdle's syndrome). N Engl J Med 1961;264:223-6.
11. Tarui S, Okuno G, Ikura Y, Tanaka T, Suda M, Nishikawa M. Phosphofructokinase deficiency in skeletal muscle: A new type of glycogenosis. Biochem Biophys Res Commun 1965;19: 517-23.
12. DiMauro S, Melis-DiMauro P. Muscle carnitine palmitoyltransferase deficiency and myoglobinuria. Science 1973;182: 929-31.
13. a ed. New York: McGraw-Hill, 1994;1577-86.
14. Fishbein WN, Armbrustmacher VW, Griffin JL. Myoadenylate deaminase deficiency: A new disease of muscle. Science 1978;299:545-8.
15. Fishbein WN. Myoadenylate deaminase deficiency. En: Engel AG, Banker BQ, editores. Myology. New York: McGraw-Hill, 1986;1745-62.
16. Andreu AL, Hanna MG, Reichmamn H, Bruno C, Penn AS, Tanji K, et al. Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N Engl J Med 1999;341:1037-44.
17. Servidei S, DiMauro S. Disorders of glycogen metabolism. Neurol Clin 1989;7:159-78.
18. DiMauro S, Arnold S, Miranda AF, Rowland LP. McArdle disease: The mistery of reappearing phosphorylase activity in muscle culture. A fetal isoenzyme. Ann Neurol 1978;3:60-6.
19. Mommaerts WF, Illinworth B, Pearson CM, Guillory RJ, Seraydarian KA. A functional disorder of muscle associated with the absence of phosphorylase. Proc Natl Acad Sci USA 1959;45:791-7.
20. Schmidt R, Mahler R. Chronic progressive myopathy with myoglobinuria. Demonstration of a glycogenolytic defect in the muscle. J Clin Invest 1959;38:2044-58.
21. a Ed. Boston: Butterworth-Heinemann, 1996;1067-97.
22. Braakhekke JP, Bruin MI, Stegeman DF, Wevers RA, Binkhorst RA, Joosten EM. The second wind phenomenon in McArdle's disease. Brain 1986;109:1087-101.
23. Tonin P, Lewis P, Servidei S, DiMauro S. Metabolic causes of myoglobinuria. Ann Neurol 1990;27:181-5
24. Engel WK, Eyerman EL, Williams HZ. Late-onset type of skeletal muscle phosphorylase deficiency: A new familial variety with completely and partially affected subjects. N Engl J Med 1963;268:135
25. Pourmand R, Sanders DB, Corwin HM. Late-onset McArdle's disease with unusual electromyographic findings. Arch Neurol 1983;40:374-97.
26. DiMauro S, Hartlage P. Fatal infantile form of muscle phosphorylase deficiency. Neurology 1978;28:1124-9.
27. De La Maza M, Patten BM, Williams JC, Chambers JP. Myophosphorylase deficiency: A new cause of infantile hypotonia simulating infantile muscular atrophy. Neurology 1983;33:1383-7.
28. Milstein JM, Herron TM, Haas JE. Fatal infantile phosphorylase deficiency. J Child Neurol 1989;4:186-8.
29. DiMauro S, Bresolin N. Phosphorylase deficiency. En: Engel AG, Banker BQ, editores. Myology. New York: McGraw-Hill, 1986;1585-1601.
30. Di Mauro S, Papadimitriou A. Carnitine palmitoyltransferase deficiency. En: Engel AG, Banker BQ, editores. Myology. New York: McGraw-Hill, 1986;1697-708.
31. Tsujino S, Shanske S, DiMauro S. Molecular genetic heterogeneity of myophosphorylase deficiency (McArdle disease). N Engl J Med 1993;329:241-5.
32. Martin MA, Rubio JC, Buchbinder J, Fernandez-Hojas R, del Hoyo P, Teijeira S, et al. Molecular heterogeneity of myophosphorylase deficiency (McArdle's disease): A Genotype-Phenotype Correlation Study. Ann Neurol 2001;50:574-81.
33. Rubio JC, Martin MA, Campos Y, Auciello R, Cabello A, Arenas J. A missense mutation W797R in the myophosphorylase gene in Spanish patient with McArdle's disease. Muse Nerv 2000;23:129-31.
34. Fernandez R, Navarro C, Andreu AL, Bruno C, Shanske S, Gamez J, et al. A novel missense mutation (W797R) in the myophosphorylase gene in Spanish patients with McArdle's disease. Arch Neurol 2000;57:217-9.
35. El-Schahawi M, Tsujino S, Shanske S, DiMauro S. Diagnosis of McArdle's disease by molecular genetic analysis of blood. Neurology 1996;47:579-80.
36. Bartram C, Edwards RH, Clague J, Beynon RJ. McArdle's disease: a nonsense mutation in exon 1 of muscle glycogen phosphorylase gene explains some but not all cases. Hum Mol Genet 1993;2:1291-3.
37. Vorgerd M, Kubisch C, Burwinkel B, Reichmann H, Mortier W, Tettenborn B, et al. Mutation analysis in myophosphorylase deficiency (McArdle's disease). Ann Neurol 1998;43:326-31.
38. Martinuzzi A, Tsujino S, Vergani L, Schievano G, Cadaldini M, Bartoloni L, et al. Molecular characterization of myophosphorylase deficiency in a group of patients from Northern Italy. J Neurol Sci 1996;137:14-9.
39. Andreu A, Bruno C, Gamez J, Shanske S, Cervera C, Navarro C, et al. Molecular genetic analysis of McArdle's disease in Spanish patients. Neurology 1998;51:260-2.
40. Murthy MS, Pande SV. Malonyl-CoA binding site and the overt carnitine palmitoyltransferase activity reside on the opposite sides of the outer mitochondrial membrane. Proc Natl Acad Sci USA 1987;84:378-82.
41. Murthy MS, Pande SV. Characteriztion of a solubilized malonyl-CoA-sensitive carnitine palmitoyltransferase from the mitochondrial outer membrane as a protein distinct from the malonyl-CoA-insensitive carnitine palmitoyltransferase of the mitochondrial inner membrane. Biochem J 1990;268:599-604.
42. Kerner J, Hoppel C. Genetic disorders of carnitine metabolism and their nutritional management. Ann Rev Nutr 1998; 18:179-206
43. Pande SV. A mitochondrial carnitine acylcarnitine translocase system. Proc Natl Acad Sci USA 1975;72:883-7
44. Brieber LL. Carnitine. Ann Rev Biochem 1988;57:261-283,
45. Finocchiario G, Taroni F, Rocchi MLiras Martin A, Colombo I, Tarelli GT, et al. cDNA cloning, sequence analysis, and chromosomal localization of the gene for human carnitine palmitoyltransferase. Proc Natl Acad Sci USA 1991;88:661-5 [corrección 10.981).
46. Woeltje KF, Esser V, Wis BC, Cox WF, Mc Paul MJ, Slaugther MJ, et al. Cloning, sequencing, and expression of a cDNA encoding rat liver mitochondrial carnitine palmitoyltransferase II. J Biol Chem 1990;265:10720-5.
47. Brown NF, Esser V, González AD, Evans CT, Slaughter CA, Foster DW, et al. Mitochondrial import and processing of rat liver carnitine palmitoyltransferase II defines the amino terminus of mature protein: possibility of diferential modification of the rat an human isoforms. J Biol Chem 1991;266:15446-9.
48. a ed. Boston: Butterworth-Heinemann, 1996;939-56.
49. Thuillier L, Sevin C, Demaugre F, Brivet M, Rabier D, Droin V, et al. Genotype/phenotype correlation in carnitine palmitoyltransferase II deficiency: lessons from a compound heterozygous patient. Nerumusc Disord 2000;10:200-5.
50. Martín MA, Rubio JC, Bustos F, Del Hoyo P, Campos Y, Garcia A, et al. Molecular analysis in Spanish patients with muscle carnitine palmitoyltransferase deficiency. Musc Nerv 1999;22:941-3.
51. Britton CH, Schultz RA, Zhang B, Esser V, Foster DW, McGarry JD. Human liver mitochondrial carnitine palmitoyltransferase I: characterization of is cDNA and chromosomal localization and partial analysis of the gene. Proc Natl Acad Sci USA 1995;92:1984-8.
52. Taroni F, Verdiero E, Fiorucci S, Cavadini P, Finocchiaro G, Uziel G, et al. Molecular characterization of inherited carnitine palmitoyltransferase II deficiency. Proc Natl Acad Sci USA 1992;89:8429-43.
53. Kaufmann P, El-Schahawi M, DiMauro S. Carnitine palmitoyltransferase II deficiency: Diagnosis by molecular analysis of blood. Mol Cell Biochem 1997;174:237-9.
54. Taggart RT, Samil D, Apolito C, Valdutiu GD. Novel mutations associated with carnitine palmitoyltransferase II deficiency. Hum Mutat 1999;13:210-20.
55. Martín MA, Rubio JC, del Hoyo P, Garcia A, Bustos F, Campos Y, et al. Identification of novel mutations in Spanish patients with muscle carnitine palmitoyltransferase II deficiency. Hum Mutat 2000;15:579-578 (Mutation In Brief On Line #332).
56. Gross M. Clinical heterogeneity and molecular mechanisms in inborn muscle AMP deaminase deficiency. J Inher Metab Dis 1997;20:186-92.
57. Mercelis R, Martin JJ, de Barsy T, Van der Berghe G. Myoadenylate deaminase deficiency: absence of correlation with exercise intolerance in 452 biopsies. J Neurol 1987;234:385-9
58. Shumate JB. Myoadenylate deaminase dficiency - a nonfamilial, nondisease? Neurology 1983;33:1533-4.
59. a Ed. New York: McGraw-Hill, 1989;1077-184.
60. Norman B, Glenmark B, Jansson E. Muscle AMP deaminase deficiency in 2% of healthy population. Musc Nerv 1995;18:239-41.
61. Norman B, Mahnke-Zizelman DK, Vallis A, Sabina RL. Genetic and other determinants of AMP deaminase activity in healthy adult skeletal muscle. J Appl Physiol 1998;85:1273-8.
62. Tsujino S, Sahnske S, Carroll JE, Sabina RL, DiMauro S. Double-trouble: Combined myophosphorylase and AMP deficiency in a child homozygous for non-sense mutations at both loci. Neuromusc Disord 1995;5:263-6.
63. Rubio JC, Martín MA, Bautista J, Campos Y, Segura D, Arenas J. Association of genetically proven deficiencies of myophosphorylase and AMP deaminase: a second case of «double trouble». Neuromusc Disord 1997;7:387-9.
64. Bruno C, Minetti C, Shanske S, Morreale G, Bado M, Cordone G, et al. Combined defects of muscle phosphofructokinase and AMP deaminase in child with myoglobinuria. Neurology 1998;50:296-8.
65. Reuschenbach C, Zierz S. Mutant carnitine palmitoyltransfersase deficiency associated with myoadenylate deaminase deficiency in skeletal muscle. J Pediatr 1988;112:600-3.
66. Sabina RL. Myoadenylate deaminase deficiency: A common inherited defect with heterogeneous clinical presentation. Neurol Clin North Am 2000;18:185-94.
67. Morisaki H, Morisaki T, Newby LK, Holmes EW. Alternative splicing: a mechanism for phenotypic rescue of a common inherited defect. J Clin Invest 1993;91:2275-80.
68. Morisaki T, Gross M, Morisaki H, Pongratz D, Zöllner N, Holmes EW. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Nat Acad Sci USA 1992;89:6457-61.
69. Verzijl HT, van Engelen BG, Luyten JA, Steenbergen GC, van den Heuvel LP, ter Laak HJ, et al. Genetic characteristics of myoadenylate deaminase deficiency. Ann Neurol 1998;44:140-3.
70. Fishbein WN. Primary, secondary, and coincidental types of myoadenylate deaminase deficiency. Ann Neurol 1999;45:547
71. Rubio JC, Martín MA, del Hoyo P, Bautista J, Campos Y, Segura D, et al. Molecular analysis of Spanish patients with AMP deaminase deficiency. Musc Nerv 2000;23:1175-8.
72. Abe M, Higuchi I, Morisaki H, Morisaki T, Osame M. Myoadenylate deaminase deficiency with progressive muscle weakness and atrophy caused by new missense mutations in AMPD1 gene: case report in a Japanese patient. Neuromuscul Disord 2000;10:472-7.
73. Arenas J, Campos Y, Martin MA, DiMauro S, Andreu AL. How wide are mitochondria involved in exercise intolerance? En: Desnuelle C, DiMaruro S, editores. Mitochondrial disorders, from pathophysiology to adquired defects. Paris: Springer-Verlag, 2002;255-6.
74. DiMauro S, Bonilla E. Mitochondrial encephalomyopathies. En: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, editores. The molecular and genetic basis of neurological disease. Boston: Butterworth-Heinemann, 1997;201-35.
75. Leonard JV, Shapira AHV. Mitochondrial respiratory chain disorders I: mitochondrial DNA defect. Lancet 2000;3555:299-304
76. Schwartz M, Vissing J. Paternal inheritance of mitochondrial DNA. N Engl J Med 2002;347:576-80.
77. Smeitnik J, van de Heuvel L, DiMauro S. The genetics and pathology of oxidative phosphorylation. Nat Rev Genet 2001;2:342-52.
78. DiMauro S, Andreu AL. Mutations in mtDNA: are we scraping the bottom of the barrel? Brain Pathol 2000;10:431-41.
79. Chinnery Pf, Johnson MA, Taylor RW, Lightowlers RN, Turnbull DM. A novel mitochondrial trna phenylalanine mutation presenting with acute rhabdomyolysis. Ann Neurol 1997;41:408-10.
80. Sobreira C, Hirano M, Shanske S, Keller RK, Haller RG, Davidson E, et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology 1997;48:1238-43.
81. Keightley A, Hoffbuhr KC, Burton MD, Salas VM, Johnston WSW, Penn AMW, et al. A microdeletion in cytochrome c oxidase (COX) subunit III associated with COX deficiency and recurrent myoglobinuria. Nat Genet 1996;12:410-5.
82. Karadimas CL, Greenstein P, Sue CM, Joseph JT, Tanji K, Haller RG, et al. Recurrent myoglobinuria due to a nonsense mutation in the COX I gene of mitochondrial DNA. Neurology 2000;55:644-9.
83. Andreu AL, Tanji K, Bruno C, Hadjigeorgiou GM, Sue CM, Jay C, et al. Exercise intolerance due to a nonsense mutation in the mtDNA ND4 gene. Ann Neurol 1999;45:820-3.
84. Musumeci O, Andreu AL, Shanske S, Bresolin N, Comi GP, Rothstein R, et al. Intragenic inversion of mtDNA: A new type of pathogenic mutation in a patient with mitochondrial myopathy. Am J Hum Genet 2000;66:1900-4.
85. Dumoulin R, Sagnol I, Ferlin T, Bozon D, Stepien G, Mousson B. A novel gly290asp mitochondrial cytochrome b mutation linked to a complex III deficiency in progressive exercise intolerance. Mol Cell Probes 1996;10:389-91.
86. Arenas J, Fernández-Moreno MA, Molina JA, Fernández V, del Hoyo P, Campos Y, et al. Myoglobinuria and COX deficiency in a patient taking crivastatin and gemfibrozil. Neurology 2003;60:124-36
87. Flint O, masters B, Gregg R, Durham S. HMG-CoA reductase inhibitor-induced myotoxicity: pravastatin an lovastatin inhibit the geranylgeranylation of the low molecular weight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol 1997;145:99-100
88. Tsukihara T, Aoyama H, Yamashita E, Tomizaki T, Yamaguchi H, Shinzawa-Itoh K, et al. The whole structure of 13-subunit oxidezed cytochrome c oxidase at 2.8 A. Science 1996;272:1136-44.